Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Advocacy of Precision Allergy Molecular Diagnosis in Decision-Making for Eligibility of Customized Allergen Immunotherapy

Version 1 : Received: 20 November 2023 / Approved: 22 November 2023 / Online: 22 November 2023 (14:45:35 CET)

A peer-reviewed article of this Preprint also exists.

González-Pérez, R.; Poza-Guedes, P.; Pineda, F.; Sánchez-Machín, I. Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy. Curr. Issues Mol. Biol. 2023, 45, 9976-9984. González-Pérez, R.; Poza-Guedes, P.; Pineda, F.; Sánchez-Machín, I. Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy. Curr. Issues Mol. Biol. 2023, 45, 9976-9984.

Abstract

Allergen immunotherapy (AIT) with aeroallergens is the only disease modifying treatment for patients with different allergic conditions. Despite the effectiveness of AIT has been evidenced in both randomized controlled trials and real word studies, it remains underused in less than 10% of subjects with allergic rhinitis (AR) and/or asthma (A). We aimed to determine the current eligibility for house dust mite (HDM) AIT by means of a Precision Allergy Molecular Diagnosis (PAMD@) model in a selected cohort of youngsters with different allergic phenotypes according to the available evidence. A complex response to both HDM and storage mite allergens was depicted regardless of the subjects´ basal atopic condition. No solely specific IgE binding responses to Der p 1, Der p 2 and/or Der p 23 were found in the studied cohort. Despite patients with A and atopic dermatitis showed significantly higher serum titers to 6 mite allergens than subjects with AR, no specific molecular profile could be regarded as disease specific. Given the increasing complexity of specific IgE responses to the local prevailing aeroallergens, the identification and presence of such molecules are needed in commercially available AIT in the era of precision medicine.

Keywords

Mites; Allergen Immunotherapy; Molecular Allergology; Allergens; Allergic Phenotype

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.